So Hyun Ahn1, Woo Sang Ahn2, Dong Hyeok Choi3, Seong Soo Shin4, Jin Sung Kim5. 1. Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea; anidol@ulsan.ac.kr mpsohyun@gmail.com. 2. Department of Radiation Oncology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Republic of Korea anidol@ulsan.ac.kr mpsohyun@gmail.com. 3. Department of Medicine, Yonsei University, Seoul, Republic of Korea. 4. Department of Radiation Oncology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Republic of Korea. 5. Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Abstract
BACKGROUND/AIM: The purpose of this study was to determine whether a semi-cylindrical beam spoiler (sCBS) developed herein effectively increases the skin dose in patients with early-stage glottic cancer. PATIENTS AND METHODS: We measured the surface doses for 26 patients who used the sCBS during treatment of early-stage glottic cancer through a parallel-opposed lateral two-field 6 MV photon beam. Measurements were performed by attaching optically stimulated luminescent dosimeters to the left, right, anterior (in-field), inferior, and superior (out-field) sides of the patient. RESULTS: The measured results were 81.8±2.1% (left), 81.0±1.7% (right), and 76.8±2.7% (anterior) in the in-field region compared to prescription doses, with 5.7±1.7% (superior) and 2.7±0.7% (inferior) in the out-field region. CONCLUSION: sCBS can deliver a suitably ideal surface dose for treatment of early-stage glottic cancer.
BACKGROUND/AIM: The purpose of this study was to determine whether a semi-cylindrical beam spoiler (sCBS) developed herein effectively increases the skin dose in patients with early-stage glottic cancer. PATIENTS AND METHODS: We measured the surface doses for 26 patients who used the sCBS during treatment of early-stage glottic cancer through a parallel-opposed lateral two-field 6 MV photon beam. Measurements were performed by attaching optically stimulated luminescent dosimeters to the left, right, anterior (in-field), inferior, and superior (out-field) sides of the patient. RESULTS: The measured results were 81.8±2.1% (left), 81.0±1.7% (right), and 76.8±2.7% (anterior) in the in-field region compared to prescription doses, with 5.7±1.7% (superior) and 2.7±0.7% (inferior) in the out-field region. CONCLUSION: sCBS can deliver a suitably ideal surface dose for treatment of early-stage glottic cancer.
Authors: Joerg Lehmann; Leon Dunn; Jessica E Lye; John W Kenny; Andrew D C Alves; Andrew Cole; Andre Asena; Tomas Kron; Ivan M Williams Journal: Med Phys Date: 2014-06 Impact factor: 4.071
Authors: David L Schwartz; Adam S Garden; Shalin J Shah; Gregory Chronowski; Samir Sejpal; David I Rosenthal; Yipei Chen; Yongbin Zhang; Lifei Zhang; Pei-Fong Wong; John A Garcia; K Kian Ang; Lei Dong Journal: Radiother Oncol Date: 2013-01-29 Impact factor: 6.280
Authors: Chi-Chung Tong; Kwok-Hung Au; Roger K C Ngan; Sin-Ming Chow; Foon-Yiu Cheung; Yiu-Tung Fu; Joseph S K Au; Stephen C K Law Journal: Radiat Oncol Date: 2011-05-21 Impact factor: 3.481
Authors: Emily Neubauer; Lei Dong; David S Followill; Adam S Garden; Laurence E Court; R Allen White; Stephen F Kry Journal: Radiat Oncol Date: 2012-02-08 Impact factor: 3.481